uniQure (NASDAQ:QURE) Reaches New 1-Year High Following Analyst Upgrade

uniQure (NASDAQ:QURE)’s share price hit a new 52-week high during trading on Monday after Stifel Nicolaus raised their price target on the stock from $12.00 to $32.00. Stifel Nicolaus currently has a buy rating on the stock. uniQure traded as high as $17.63 and last traded at $17.54, with a volume of 1889446 shares. The stock had previously closed at $15.40.

A number of other equities research analysts have also commented on QURE. StockNews.com raised uniQure to a “sell” rating in a research report on Wednesday, December 11th. Royal Bank of Canada raised their target price on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Cantor Fitzgerald raised their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of uniQure in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.13.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. RTW Investments LP bought a new stake in shares of uniQure in the third quarter valued at about $49,000. China Universal Asset Management Co. Ltd. grew its position in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new position in shares of uniQure during the third quarter worth approximately $53,000. Quarry LP acquired a new stake in shares of uniQure in the third quarter valued at approximately $58,000. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,306 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Stock Up 13.9 %

The stock has a 50-day moving average of $7.04 and a 200-day moving average of $6.38. The firm has a market cap of $854.95 million, a price-to-earnings ratio of -3.36 and a beta of 0.89. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. Sell-side analysts predict that uniQure will post -3.82 EPS for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.